Galderma Group AG (GALDY)
Healthcare · PNK · US
Price as at 1 Oct 2026, 21:20 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Galderma Group AG trades at $38.76, which is 27% above the $28.11 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 73 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 54.6 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
GALDY dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.089 | 1 |
| 2025 | $0.036 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
GALDY earnings and analyst estimates
Recommendation mix, 1 published rating
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
GALDY passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Politician trades in GALDY
Trades in GALDY disclosed by members of Congress and executive-branch officials, latest first:
- Alan Armstrong · SenateBuy · $1,001 - $15,000 · traded 30 Mar 2026 · disclosed 21 Jul 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
GALDY peers
The largest companies in the same industry (Drug Manufacturers - Specialty & Generic), then in the same sector.
- TKPHF Takeda Pharmaceutical Company Limited
- JHPCY JHPCY
- HLNCF Haleon plc
- TEVA Teva Pharmaceutical Industries Limited
- UTHR United Therapeutics Corporation
- VTRS Viatris Inc.
- NBIX Neurocrine Biosciences, Inc.
- ELAN Elanco Animal Health Incorporated
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Galderma Group AG (GALDY) undervalued?
Against our fair value estimate of $28.11, GALDY at $38.76 is 27% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
What is GALDY's P/E ratio?
GALDY trades at 54.6 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Galderma Group AG (GALDY) pay a dividend?
Yes. Galderma Group AG yields 0.22% at the current share price. It has paid $0.089 per share over the trailing twelve months. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its GALDY data?
Fundamentals for GALDY come from company filings and exchange data, as listed on PNK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 21:20 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for GALDY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.